Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program

NCT03768817

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

COMPLETED

Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects

NCT02201368

Long-chain Fatty Acid Transport Deficiency

WITHDRAWN PHASE3

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies

NCT02214160

Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency +2 more

COMPLETED PHASE2

Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids

NCT00328159

Inborn Errors of Metabolism

COMPLETED NA

Effects of Carnitine Supplementation on Liver and Muscle

NCT03439917

Non-Alcoholic Fatty Liver Disease Insulin Resistance

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recruitment: Patients with a long-chain fatty acid oxidation disorder will be recruited through our clinic, past research participants, a patient support website, and recruitment letters mailed to physicians around the US. We will enroll 16 subjects at OHSU and 16 subjects at the University of Pittsburgh, age 7 to 40, with a disorder in fatty acid oxidation.

Procedures: Subjects will be admitted to the clinical research center for 4 days. They will collect all their urine for 24 hours. Heart function will be measured using ultrasound an electrocardiogram (ECG). The motion of the heart will be measured by magnetic resonance imaging (MRI). For this test, the patient lies in the magnetic field of the MRI machine in the Advanced Imaging Resource Center (AIRC) for about 45 minutes. The amount of muscle and fat in the whole body and inside the liver and muscle will be measured by MRS and by dual X-ray absorptiometry (DEXA). Subjects will walk on a treadmill for about 45 minutes. The amount of Calories they use, their heart rate, and if they burn fat or carbohydrates will be measured. Blood samples will be collected before and after exercise. A meal test will be used to determine how much fat they burn. The subjects will drink a liquid breakfast with a stable isotope labeled fat in the breakfast. Breath and blood samples will be collected before and after the meal. The amount Calories burned by each subject will be measured when they are at rest on a bed by indirect calorimetry. The amount of Calories burned by subjects when they are doing their routine daily activities will be measured at home by doubly labeled water. All of these tests will be done at baseline. Then, subjects will be randomly assigned to consume MCT (current standard of care) or triheptanoin at 20% of their estimated Calorie needs for 4 months. The subject and/or the parent will be taught how to use the supplement oil in their diet for cooking and baking. The subject will be sent home and the oil will be shipped to their home. The study coordinator will call the subject or subject's guardian each week to monitor the subject's diet, potential side effects and assist with diet planning. At the end of 4 months, all of the baseline tests will be repeated.

Triheptanoin is experimental oil. It is a clear, odorless oil that can be mixed with foods and used in cooking. Almost all oils are made from even chains of carbon molecules. Triheptanoin is different because the carbon chains are odd in number. The co-investigator of this study at the University of Pittsburgh, Dr. Jerry Vockely, holds an IND for the prescription, and use of triheptanoin in humans (IND 106011).

Data Analysis: The change in exercise ability, heart function, Calories used and body fat after 4 months will be compared between subjects randomized to MCT versus triheptanoin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency Carnitine Palmitoyltransferase 2 (CPT2) Deficiency Mitochondrial Trifunctional Protein (TFP) Deficiency Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medium Chain Triglyceride (MCT)

Subjects randomized to consume 20% of energy from MCT

Group Type ACTIVE_COMPARATOR

Triheptanoin

Intervention Type DRUG

Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone

Triheptanoin

Subject randomized to consume 20% of energy from triheptanoin.

Group Type EXPERIMENTAL

Triheptanoin

Intervention Type DRUG

Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triheptanoin

Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IND 113386 C7

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of Very long-chain acylCoA dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency, or Long-chain 3 hydroxyacylCoA dehydrogenase (LCHAD) deficiency
* \> 7 years
* Ability to travel to CRC to participate
* Ability to follow protocol

Exclusion Criteria

* Hgb \< 10 g/dl
* Peripheral neuropathy that limits ability to complete treadmill studies
* Inclusion in another research study that alters macronutrient intake
* Pregnant females
* history of myocardial infarction or cardiovascular disease

Minimum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No